Pfizer’s move to dump it’s neuroscience divisions caused serious ripples through the industry, with many wondering whether it heralded an end of big pharma’s interest in the notoriously difficult to target disease area, which includes the illusive targets of Alzheimer’s and Parkinson’s disease.
Reageer